Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

J Immunother Cancer · 2019 · PMC6542114 · PMID 31142380

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In preclinical studies, the dual-specific immunotoxin D2C7-IT demonstrated a strong antitumor response against intracranial glioblastoma xenografts expressing EGFRwt only and both EGFRwt and EGFRvIII, resulting in a highly significant increase in survival in the tumor-bearing animals with no viable tumor cells at the termination of the experiment.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.